Connect with us

Nation

Twitter stops opening links in AMP on iOS and Android

Published

on

twitter 1

 

 

Twitter has quietly rolled back its support for Accelerated Mobile Pages (AMP) on mobile, according to a support page spotted by SEO consultant Christian Oliveira.

 

The support page originally detailed how Twitter would automatically send users of its mobile apps to the AMP version of a page from links posted on the social network.

 

However, at some point since October 21st; Twitter updated the page with a notice saying it’s retiring the feature by the end of the year.

 

According to data from SearchEngineLand, this retirement process appears to have been completed earlier this month. Now, attempting to visit a page from Twitter appears to send users directly to the regular web page, rather than an AMP version that may be available.

 

Although Twitter notes that the AMP allows for “fast-loading, beautiful; high-performing mobile web experiences,” the technology has proved controversial since Google introduced it in 2015.

 

Much of the controversy centered around Google’s perceived control of the project; with some critics claiming that it amounted to Google’s attempt to reinforce its control of the open web.

 

But it also has more basic user interface problems for a platform like Twitter because of the way it can mess with URLs; when it makes pages appear to be from Google regardless of the website that created them.

 

It’s an annoying situation that’s led to the creation of browser extensions which automatically redirect AMP pages to the original article URL to reduce confusion.

Twitter’s support document doesn’t give a reason for its change in policy.

 

A spokesperson was not immediately available to respond to a request for comment.

 

The social network’s move follows a policy change from Google itself in May 2020; when it announced that it would no longer require news sites to offer AMP versions of their pages in order to be featured in its search engine’s Top Stories section.

 

The move was a long time coming following a Google initiative launched in May 2018; to take what the company had learned from AMP and turn its features into general web standards.

 

For more background on AMP, check out this 2018 episode of The Vergecast; featuring an interview with AMP’s former tech lead Malte Ubl.

Nation

Vaccine makers move quickly against new omicron Covid variant, testing already under way

Published

on

vaccine health coronavirus pfizer children 1

 

 

The world’s major manufacturers of Covid-19 vaccines said Friday; that they are working to quickly investigate and adapt their shots to a new and highly mutated strain of the virus.

 

The World Health Organization on Friday said the new strain; named omicron, is a “variant of concern” that may pose a higher risk of reinfection than past mutations of the virus.

Pfizer and BioNTech said they are investigating omicron, first labeled B.1.1.529, and can adapt their vaccine quickly if needed.

 

“We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” the companies said.

 

Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.

 

“These data will provide more information about whether B.1.1.529 could be an escape variant; that may require an adjustment of our vaccine if the variant spreads globally,” the companies said.

 

Pfizer and BioNTech said they can adapt their mRNA vaccine within six weeks and start shipping batches within 100 days if an escape variant is identified.

Johnson & Johnson on Friday said they were already testing their vaccine against omicron.

 

“We are closely monitoring newly emerging COVID-19 virus strains with variations in the SARS-CoV-2 spike protein and are already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in southern Africa,” J&J said.

 

AstraZeneca said it is also investigating the variant.

 

Its vaccine platform developed with Oxford University enables a quick response to new mutations as they emerge; the company said.

 

“AstraZeneca is also already conducting research in locations where the variant has been identified; namely in Botswana and Eswatini,” the company said.

 

Moderna, in a statement Friday; said the combination of mutations in the variant “represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity.”

 

“A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity,” the company said.

 

Moderna said it will test three booster candidates against omicron, including at a higher dosage level.

 

The company will also develop a booster dose specific to the variant.

 

“From the beginning, we have said that as we seek to defeat the pandemic; it is imperative that we are proactive as the virus evolves,” said Moderna CEO Stephane Bancel in a statement. “The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible; to execute our strategy to address this variant.”

 

The variant, which emerged in South Africa, has about 50 mutations; more than 30 of which are on the spike protein that allows the virus to bind to human cells.

 

The spread of the new variant is still in its early stages; and it’s also not yet clear how severe an infection would be to a vaccinated person.

 

Several European as well as Asian nations have suspended flights from southern Africa in response to the variant.

 

The United Kingdom suspended flights on Thursday from six countries in the region, and the European Commission – the European Union’s executive body – told all 27 member states to halt travel from southern Africa.

 

White House chief medical advisor Dr. Anthony Fauci on Friday said the U.S. is working with South African scientists to obtain the molecular makeup of the variant so lab tests can be conducted.

 

Those tests would help determine whether or not the variant can evade antibody protection provided by the vaccines.

 

Fauci said that data would help determine whether or not the U.S. should implement similar travel restrictions.

 

The Biden administration confirmed later on Friday that; the U.S. would restrict entry for non-citizens coming from eight southern African nations.

 

The strength of Covid vaccines against infection has declined over time although they’re still highly effective at preventing hospitalization and death.

ALSO READ: BioNTech to update its Covid jab within 100 days amid efficiency concerns against Omicron

 

A study published in the journal Science this month found that; the Pfizer vaccine’s efficacy at preventing infection declined from 86% to 43% from February to October.

 

Moderna’s vaccine dropped from 89% to 58%, and J&J’s vaccine also fell from 86% to 13% efficacy against infection in the same study.

 

The U.S. Centers for Disease Control and Prevention authorized booster shots of Pfizer-BioNTech’s and Moderna’s vaccines for all adults last Friday.

 

The Pfizer booster dose was 95% effective at preventing symptomatic infection in people; who had no evidence of prior infection in a clinical trial of 10,000 participants ages 16 and older, according to the company.

 

Moderna is still conducting a clinical trial on the efficacy of its booster dose.

Continue Reading

Nation

UK: Online training for veterinary Wholesale Qualified Persons (WQPs)

Published

on

s960 WQP 4


Ben Nsemo

UK: Online training for veterinary Wholesale Qualified Persons (WQPs)

Details of an online training course for veterinary Wholesale Qualified Persons (WQPs).

Source: GOV.UK

Continue Reading

Nation

UK: Online training for veterinary Wholesale Qualified Persons (WQPs)

Published

on

s960 WQP 4


Ben Nsemo

UK: Online training for veterinary Wholesale Qualified Persons (WQPs)

Details of an online training course for veterinary Wholesale Qualified Persons (WQPs).

Source: GOV.UK

Continue Reading

Trending